Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

Vivani Medical, Inc. ( ($VANI) ) has released its Q2 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its ...

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a Share Purchase Agreement to sell 7,936,507 ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTMimplant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met t ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.